Oculis Appoints Björn Tackenberg as Chief Scientific Officer

PUBT · 2d ago
Oculis Appoints Björn Tackenberg as Chief Scientific Officer
  • Oculis appointed Björn Tackenberg chief scientific officer; he previously headed Integrative Neuroscience & Medical Practice at Roche.
  • Tackenberg will lead global scientific strategy, prioritizing Privosegtor's PIONEER program and potential applications in acute multiple sclerosis relapses.
  • Aaron Tansy recently joined as vice president, development franchise head, neurology; he previously served as executive medical director, clinical development at PTC Therapeutics.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oculis Holding AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611020200PRIMZONEFULLFEED1001301109) on November 02, 2026, and is solely responsible for the information contained therein.